Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cytokine-induced killer cells

A preparation of cytokine-induced killer (CIK) cells, with potential immunopotentiating and antineoplastic activities. CIK cells are generated from peripheral blood lymphocytes (PBLs) by sequential ex vivo incubation with a monoclonal antibody against CD3 (anti-CD3), interferon-gamma (IFN-g) and interleukin-2 (IL-2), followed by expansion. CIK cells are heterogeneous cells comprising CD3+CD56- T cells, CD3-CD56+ natural killer (NK) cells, and CD3+CD56+ natural killer T (NKT) cells. Upon administration of the CIK cells into the patient, the terminally differentiated CD3- and CD56-positive subset of the CIK cells primarily exert the direct MHC-unrestricted tumor killing activity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Abbreviation:CIK
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search